Assays for PD-L1 expression: Do all roads lead to Rome?
Menée à partir de 90 échantillons tumoraux archivés après prélèvement sur des patients atteints d'un cancer du poumon non à petites cellules, cette étude évalue la performance de quatre tests immunohistochimiques pour mesurer l'expression de PD-L1
Inhibition of the programmed cell death 1 protein (PD-1) pathway reverses T-cell exhaustion and improves survival relative to standard chemotherapy for patients with advanced stages of non–small cell carcinoma (NSCLC).1- 3 Since the clinical benefit is restricted to a subset of patients, predictive biomarkers are essential for patient selection. A number of putative markers have demonstrated predictive potential, but the only proven marker to date is expression of the PD-1 ligand (PD-L1), assessed by immunohistochemistry (IHC).4
JAMA Oncology , commentaire, 2016